

Department of Defense FY18 research funding for the Congressionally Directed Medical Research Program

11 April 2018

The Congressionally Directed Medical Research Program (CDMRP) within the U.S. Army Medical Research and Materiel Command is a partnership formed by Congress and the military. It manages billions of dollars in Congressional appropriations for peer-reviewed research that discovers, develops, and delivers healthcare solutions for Service Members, Veterans, and the American public. Our legislative practice has worked with clients to secure this critical funding and can assist those interested in securing new funding opportunities.

With the passage of the FY18 Omnibus Appropriations Bill, new funding levels have been announced showing increased funding opportunities for grants within the certain disease research programs.

Research Program	FY17 Enacted Millions	FY18 Omnibus Millions	Final Change, FY17-FY18 Millions
Alcohol and Substance Abuse Research Program	\$4.0	\$4.0	\$0.0
Amyotrophic Lateral Sclerosis Research Program	\$7.5	\$10.0	\$2.5
Autism Research Program	\$7.5	\$7.5	\$0.0
Bone Marrow Failure Research Program	\$3.0	\$3.0	\$0.0
Breast Cancer Research Program	\$120.0	\$130.0	\$10.0
Duchenne Muscular Dystrophy Research Program	\$3.2	\$3.2	\$0.0
Epilepsy Research Program	\$7.5	\$7.5	\$0.0
Gulf War Illness Research Program	\$20.0	\$21.0	\$1.0
Hearing Restoration Research Program	\$10.0	\$10.0	\$0.0
Kidney Cancer Research Program	\$10.0	\$15.0	\$5.0
Joint Warfighter Medical Research Program	\$50.0	\$50.0	\$0.0
Lung Cancer Research Program	\$12.0	\$14.0	\$2.0
Lupus Research Program	\$5.0	\$5.0	\$0.0
Military Burn Research Program	\$8.0	\$8.0	\$0.0
Multiple Sclerosis Research Program	\$6.0	\$6.0	\$0.0
Neurofibromatosis Research Program	\$15.0	\$15.0	\$0.0

Orthotics and Prosthetics Outcomes Research Program	\$10.0	\$10.0	\$0.0
Ovarian Cancer Research Program	\$20.0	\$20.0	\$0.0
Parkinson's Research Program	\$16.0	\$16.0	\$0.0
Peer Reviewed Alzheimer's Research Program	\$15.0	\$15.0	\$0.0
Peer Reviewed Cancer Research Program (14 Topics)	\$30.0	\$80.0	\$50.0
Peer Reviewed Medical Research Program (48 Topics)	\$300.0	\$330.0	\$30.0
Peer Reviewed Orthopaedic Research Program	\$30.0	\$30.0	\$0.0
Prostate Cancer Research Program	\$90.0	\$100.0	\$10.0
Reconstructive Transplant Research Program	\$12.0	\$12.0	\$0.0
Spinal Cord Injury Research Program	\$30.0	\$30.0	\$0.0
Tick-Borne Disease Research Program	\$5.0	\$12.0	\$7.0
Trauma Clinical Research Program	\$10.0	\$10.0	\$0.0
Tuberous Sclerosis Complex Research Program	\$6.0	\$6.0	\$0.0
Vision Research Program	\$15.0	\$15.0	\$0.0

Department of Defense FY18 Appropriations for Peer Reviewed Cancer Research Program (PRCRP)

The FY18 funding level for the *Peer Reviewed Cancer Research Program (PRCRP)* is US\$80 million, which is an increase of US\$20 million over the FY17 level. The mission of the PRCRP is to successfully promote high-impact research for cancer prevention, detection, treatment, and survivorship. Topic areas can vary annually. In FY18, the PRCRP is directed to support research in the following areas:

- Adrenal cancer
- Brain cancer
- Melanoma and other
- Listeria-based regimens for cancer
- Neuroblastoma
- Stomach cancer
- Bladder cancer
- Colorectal cancer
- Liver cancer
- Mesothelimoa
- Pancreatic cancer
- Cancer in children, young adolescents, and young adults
- Blood cancers
- Immunotherapy
- Lymphoma
- Myeloma
- Pediatric brain tumors

Department of Defense FY18 Appropriations for Peer Reviewed Medical Research Program (PRMRP)

The FY18 funding level for the *Peer Reviewed Medical Research Program (PRMRP)* is US\$330 million, which is an increase of US\$30 million over the FY17 level. The mission of the PRMRP is to identify and select military health-related research of exceptional scientific merit.

In FY18, the PRMRP will support 52 topic areas, which is an increase from the 48 topic areas supported in FY17. In FY18, the PRMRP is directed to support research in the following areas:

- Acute lung injury
- Burn pit exposure
- Chronic migraine and post-traumatic headache
- Constrictive bronchiolitis
- Eating disorders
- Epidermolysis bullosa
- Frontotemporal degeneration
- Antimicrobial resistance
- Cardiomyopathy
- Chronic pain management
- Diabetes
- Emerging infectious diseases
- Focal segmental glomerulosclerosis
- Arthritis
- Cerebellar ataxia
- Congenital heart disease
- Dystonia
- Endometriosis
- Fragile X
- Hepatitis B and C
- Immunomonitoring of

- Hereditary angioedema
- Inflammatory bowel diseases
- Malaria
- Musculoskeletal disorders
- Nutrition optimization
- Post-traumatic osteoarthritis
- Respiratory health
- Scleroderma
- Sustained-release drug delivery
- Tuberculosis
- Women’s heart disease
- Guillain-Barre syndrome
- Hydrocephalus
- Interstitial cystitis
- Metals toxicology
- Myotonic dystrophy
- Pancreatitis
- Pressure ulcers
- Rett syndrome
- Sleep disorders
- Tinnitus
- Vaccine development for infectious disease
- intestinal transplants
- Lung injury
- Mitochondrial disease
- Non-opioid pain management
- Pathogeninactivated blood products
- Pulmonary fibrosis
- Rheumatoid arthritis
- Spinal muscular atrophy
- Tissue regeneration
- Vascular malformations

Contacts



Michael Gilliland
 Senior Counsel, Washington, D.C.
 T +1 202 637 5619
mike.gilliland@hoganlovells.com



Kate McAuliffe
 Counsel, Washington, D.C.
 T +1 202 637 6438
kate.mcauliffe@hoganlovells.com

www.hoganlovells.com

“Hogan Lovells” or the “firm” is an international legal practice that includes Hogan Lovells International LLP, Hogan Lovells US LLP and their affiliated businesses. The word “partner” is used to describe a partner or member of Hogan Lovells International LLP, Hogan Lovells US LLP or any of their affiliated entities or any employee or consultant with equivalent standing. Certain individuals, who are designated as partners, but who are not members of Hogan Lovells International LLP, do not hold qualifications equivalent to members. For more information about Hogan Lovells, the partners and their qualifications, see www.hoganlovells.com. Where case studies are included, results achieved do not guarantee similar outcomes for other clients. Attorney advertising. Images of people may feature current or former lawyers and employees at Hogan Lovells or models not connected with the firm.
 © Hogan Lovells 2018. All rights reserved.